![]() |
|
|
Vol. 295, Issue 2, 519-523, November 2000
Cardiac Medicine, National Heart and Lung Institute, Imperial College School of Medicine, London, United Kingdom
| |
Abstract |
|---|
|
|
|---|
In epidemiological studies tamoxifen has been associated with a
reduction in the incidence of fatal myocardial infarction in women.
However, the effects of tamoxifen on coronary artery reactivity are
unknown. We hypothesized that tamoxifen would relax precontracted
isolated rabbit coronary arteries. Rings of coronary artery from adult
male and nonpregnant female New Zealand White rabbits were suspended in
organ baths containing Krebs' solution; isometric tension was
measured. Tamoxifen (0.1-100 µM) induced significant
endothelium-dependent relaxation in precontracted rabbit coronary
arteries. This relaxation was inhibited by
N
-nitro-L-arginine methyl
ester and the estrogen receptor antagonist ICI 182,780. There
was no significant effect on calcium concentration-dependent contraction curves. These data suggest that tamoxifen has beneficial effects on coronary reactivity that could, at least in part, account for the reduction in risk of fatal myocardial infarction in women taking tamoxifen.
| |
Introduction |
|---|
|
|
|---|
Tamoxifen
belongs to a group of structurally diverse compounds called selective
estrogen receptor modulators (SERMs) that are able to interact with the
estrogen receptor, but are distinguished from estrogen by an ability to
act as either an estrogen agonist or antagonist, depending on the
target tissue and hormonal milieu. Early recognition of the
tissue-specific activities of tamoxifen, the first SERM, led to the
development of new SERMs (raloxifene) that have greater tissue
selectivity. The estrogen antagonistic properties of tamoxifen are
useful in the treatment and control of breast cancer (Early Breast
Cancer Trialists' Collaborative Group, 1992
).
Epidemiological evidence suggests that tamoxifen confers a beneficial
effect on the cardiovascular system, similar to estrogen. Tamoxifen is
associated with a reduction in the incidence of fatal myocardial
infarction in women (McDonald and Stewart, 1991
; Early Breast Cancer
Trialists' Collaborative Group, 1992
), as well as suppressing
diet-induced formation of lipid lesions in mouse aorta (Grainger et
al., 1995
). Tamoxifen appears to share with estrogen the beneficial
effects on plasma lipids and lipoproteins (Rossner and Wallgren, 1984
;
Love et al., 1994
; Stevenson et al., 1994
). Estrogen relaxes coronary
arteries acutely and chronically, both in vitro and in vivo (Jiang et
al., 1991
, 1992b
; Mugge et al., 1993
; Chester et al., 1995
;
Sudhir et al., 1995
), and the mechanisms involved in this relaxation
may contribute to the cardioprotective effect of estrogen. Recently, we
have demonstrated that the SERM raloxifene shares this relaxant effect
on coronary arteries (Figtree et al., 1999
), the significance of which
is currently being investigated in postmenopausal women in an
international multicenter clinical trial called RUTH (Raloxifene Use in
The Heart) (Barrett-Connor et al., 1998
). The effects of tamoxifen on
coronary vascular reactivity are unknown, therefore we investigated the
effects of tamoxifen on rabbit coronary arteries in vitro.
| |
Materials and Methods |
|---|
|
|
|---|
Animals and Tissues.
Adult male or nonpregnant female New
Zealand White rabbits (2.5-3 kg) were sacrificed by an overdose of
pentobarbitone (60 mg kg
1) and heparin (150 units kg
1). The heart was removed and
epicardial coronary arteries were dissected free of connective tissue.
Arterial rings were prepared and in some rings the endothelium was
removed by gentle rubbing with a wooden probe. Each ring (2-3 mm in
length) was suspended horizontally between two stainless steel parallel
hooks for the measurement of isometric tension in individual organ
baths containing 10 ml of modified Krebs' solution at 37°C, bubbled
with 95% O2 and 5% C02.
The composition of modified Krebs' solution was as follows: 118.3 mM
NaCl, 4.7 mM KCl, 2.5 mM CaCl2, 1.2 mM
MgSO4, 1.2 mM
K2PO4, and 11.1 mM glucose.
Coronary arterial rings with or without endothelium from male and
female rabbits were allowed to stabilize for 90 min under a resting
tension of 1 g (9.8 mN) before being contracted. Preparations were
exposed to maximally effective concentrations of a contractile agonist
(K+, 30 mM) to ensure stabilization of the rings.
The agonist was then removed and the ring re-equilibrated. The presence
of endothelium was verified by observing the relaxation response to acetylcholine.
Effect of Tamoxifen on Precontracted Coronary Arteries. Coronary arterial rings with and without endothelium were contracted with K+ (30 mM). Increasing concentrations of the tamoxifen (0.1-100 µM) were added at half-log increments at the plateau of the previous response. The response at each concentration of tamoxifen was measured. Simultaneous time-matched control curves were constructed using an equivalent volume of solvent as that used to dissolve tamoxifen.
Effect of
N
-Nitro-L-arginine Methyl
Ester (L-NAME) on Tamoxifen-Induced Relaxation.
L-NAME is an inhibitor of nitric oxide (NO) synthesis from
L-arginine in vascular endothelial cells (Rees et al.,
1990
). L-NAME (0.1 mM) was added to coronary arterial rings
with endothelium 20 min before they were contracted with
K+ (30 mM). This concentration of
L-NAME has been demonstrated to completely inhibit
nitric-oxide synthase in rabbit aorta (Rees et al., 1989
).
Concentration-dependent responses to tamoxifen (1-100 µM) were then measured.
Effect of Barium Chloride on Tamoxifen-Induced Relaxation.
To examine the possible role of potassium conductance on
tamoxifen-induced coronary relaxation, barium chloride, a nonspecific inhibitor of potassium channels (Quayle et al., 1988
), was added to
coronary arterial rings without endothelium 20 min before their contraction with K+ (30 mM).
Concentration-dependent responses to tamoxifen (1-100 µM) were then measured.
Estrogen-Receptor Dependence of the Relaxing Response to
Tamoxifen.
To examine the possible role of the classical estrogen
receptor in mediating tamoxifen-induced relaxation, rings with
endothelium were incubated in the specific estrogen receptor antagonist
ICI 182,780 (Wakeling et al., 1991
) (10 µM) for 20 min before
precontraction in K+ (30 mM). This concentration
of ICI 182,780 was shown in single-cell studies to have
antiestrogen receptor antagonism. Measurements of the responses to
increasing concentrations of tamoxifen were then repeated.
Effect of Tamoxifen on Calcium Concentration Responses in Rabbit Coronary Arteries. Rabbit coronary arterial rings without endothelium were incubated in calcium-free solution containing 0.5 mM EGTA for 10 min. The calcium concentration-dependent contraction curves were then performed in high K+ depolarization medium (100 mM). Rings were readjusted in modified Krebs' for 20 min and then incubated in calcium-free solution containing EGTA (0.5 mM) for a further 10 min. Subsequently, rings were incubated with tamoxifen (10 µM). The calcium concentration-dependent contraction curves were then repeated.
Drugs. The following drugs were used: tamoxifen (Sigma, Poole, Dorset, UK), L-NAME (Sigma), barium chloride (Sigma), and ICI 182,780 (Tocris, Avonmouth, UK).
Data Analysis. All results are expressed as mean ± S.E. Relaxation is expressed as percentage relaxation of contraction induced by K+ (30 mM). The results were analyzed with ANOVA, and the Student-Newman-Keuls test was used for multiple comparisons. A probability level of less than .05 was considered significant. n indicates the number of animals.
| |
Results |
|---|
|
|
|---|
Relaxing Effect of Tamoxifen on Precontracted Coronary
Arteries.
K+ (30 mM) induced significant
contraction, comparable in rings with or without endothelium (Fig.
1). Tamoxifen induced significant concentration-dependent relaxation of contracted rings compared with
time-matched controls (Fig. 2).
Relaxation to tamoxifen in rings with no endothelium was significantly
less than in rings with endothelium (Fig. 2). There were no significant
differences in relaxation between arteries from male or female rabbits
in rings with endothelium (Fig. 4a).
|
|
Effect of L-NAME on Tamoxifen-Induced Relaxation.
Incubation with L-NAME (30 µM) had no significant effect
on contraction response to K+ (30 mM) (Fig. 1).
However, L-NAME significantly inhibited tamoxifen-induced relaxation in rabbit coronary arterial rings with endothelium (Fig.
3). The inhibitory effect of
L-NAME was not significantly different in rings from male
versus female rabbits (Fig. 4b).
|
|
Effect of ICI 182,780 on Tamoxifen-Induced Relaxation. Incubation in ICI 182,780 (10 µM) had no significant effect on contraction response to K+ (30 mM) (Fig. 1). However, it significantly inhibited relaxation induced by tamoxifen in rings with endothelium (Fig. 3). The inhibitory effect of ICI 182 780 was not significantly different in rings from male versus female rabbits (Fig. 4b).
Effect of Barium Chloride on Tamoxifen-Induced Relaxation. The nonspecific inhibitor of potassium channels barium chloride (3 µM) had no significant effect on contraction response to K+ (30 mM). It also had no effect on relaxation induced by tamoxifen (Fig. 3).
Calcium Antagonistic Effects of Tamoxifen in Rabbit Coronary
Arterial Rings.
Tamoxifen (10 µM) had no significant effect on
the calcium concentration-dependent contraction curves in high
K+ (100 µM) depolarization medium compared with
control. Maximal contraction was also not affected (Fig.
5).
|
| |
Discussion |
|---|
|
|
|---|
We have demonstrated that tamoxifen induces significant relaxation
in precontracted rabbit coronary arteries. This relaxation was shown to
be, at least in part, dependent on the endothelium and was able to be
inhibited by L-NAME and the estrogen receptor antagonist
ICI 182,780. Tamoxifen had no significant effect on calcium
concentration-dependent contraction curves in this preparation. The
relaxation of endothelium-denuded rings most likely occurs by a direct
effect of tamoxifen on the vascular myocyte. A similar relaxing effect
of tamoxifen on vascular reactivity has recently been observed in
cerebral arterial preparations contracted with oxyhemoglobin (Wickman
and Vollrath, 2000
).
An important aspect of this work is that we have demonstrated a
relaxant effect of tamoxifen on coronary arterial ring preparations at
concentrations at and above 3 µM. Serum concentrations of tamoxifen and its metabolites have been demonstrated to show a wide asymmetrical distribution in patients with breast cancer, depending on hepatic dysfunction, age, treatment duration, and the associated chemotherapy on tamoxifen pharmacokinetics (median, 0.4 µM; range, not detectable to 2 µM) (Peyrade et al., 1996
). Thus, the concentrations of
tamoxifen that induced coronary artery relaxation in the present study
approximate to plasma levels found in patients treated with tamoxifen.
The mechanisms of coronary relaxation by tamoxifen demonstrated in this
study may contribute to the apparent reduction in risk of cardiovascular disease in postmenopausal women taking tamoxifen (McDonald and Stewart, 1991
).
NO is synthesized in the endothelium from L-arginine by NO
synthase (Palmer et al., 1988
) and can diffuse rapidly to smooth muscle, causing relaxation via stimulation of soluble guanylate cyclase
and a subsequent increase in cyclic GMP (Rapoport et al., 1983
). By
blocking NO synthesis with L-NAME (Rees et al., 1989
) we
were able to completely abolish the difference in relaxation to
tamoxifen between rings with and without endothelium, implying that the
endothelial contribution to tamoxifen-induced relaxation is dependent
on NO.
In the present study, significant tamoxifen-induced relaxation occurred
in rings denuded of endothelium, or in which endothelial NO production
was inhibited, suggesting that tamoxifen exerts a direct relaxant
effect on vascular smooth muscle (Figs. 2 and 3). The relative
contribution of this direct effect to tamoxifen-induced coronary artery
relaxation appears to increase, compared with the endothelial
component, with increasing concentrations of tamoxifen (Fig. 3). The
lack of effect of tamoxifen on the calcium concentration-dependent contraction curve (Fig. 5) suggests that this direct smooth muscle effect is independent of calcium channel blockade. This is dissimilar to both 17
-estradiol (Jiang et al., 1992a
; Han et al., 1995
), whose actions on the vascular myocyte have been shown to involve an
inhibitory action on voltage-gated calcium channels, and raloxifene in
which the direct effect on vascular smooth muscle has also been
demonstrated to involve calcium channels (Figtree et al., 1999
). It
also differs from results using whole-cell patch-clamp studies in
vascular smooth muscle cells. Song et al. (1996)
demonstrated that
tamoxifen reduced current through L-type Ca2+
channels, with an ID50 of 2 × 10
6 M in A7r5 cells. This effect may therefore
involve other ion channels not examined in the present study. Recent
evidence that tamoxifen activates a large-conductance chloride channel
in cultured endothelial cells, supports this possibility (Li et al.,
2000
). The insignificant effect of nonspecific potassium channel
blockade with barium chloride suggests that modulation of potassium
channel opening is not an important mechanism of
endothelium-independent relaxation to tamoxifen.
We have demonstrated that the endothelium-dependent relaxation to
tamoxifen is partially inhibited by the specific estrogen receptor
antagonist ICI 182,780, suggesting that the response involves the
estrogen receptor (Wakeling et al., 1991
). This apparent estrogen
receptor dependence has also been demonstrated for raloxifene-induced relaxation in the same model (Figtree et al., 1999
). However, relaxation to estrogen, which has only been seen to be
endothelium-independent in this model (Jiang et al., 1991
), has not
been observed to be inhibited by antagonism at the estrogen receptor.
The acute nature of tamoxifen-induced coronary artery relaxation
suggests that mediation via a transcriptional effect of the
tamoxifen-estrogen-receptor complex is unlikely. Rapid activation of NO
synthase has been demonstrated in pulmonary endothelial cells within 5 min (Chen et al., 1999
). Recent findings of cell surface forms of
estrogen receptors coupled to cytosolic signal transduction proteins
provide evidence for nongenomic signaling by estrogen. This may help
explain reports of rapid estrogen effects occurring not only in the
vasculature but also in breast, bone, and neuronal tissue
(Collins and Webb, 1999
; Mendelsohn and Karas, 1999
). This may be a
mechanism similar to that by which tamoxifen and raloxifene are able to
activate endothelium-derived NO and subsequent coronary artery
relaxation. The inhibition of this relaxation by ICI 182,780 is
consistent with this hypothesis.
The mechanism by which SERMs exert differential estrogen agonistic and
antagonistic effects may be further elucidated with continued
investigations into the relative roles of the classic estrogen receptor
, and the more recently discovered estrogen receptor
(Gustafsson, 1997
), as well as the surface estrogen receptor(s)
(Collins and Webb, 1999
). A differential action of each SERM on the
respective estrogen receptors may relate to the relative
agonist/antagonistic effect seen in response to each when administered
to tissues expressing different receptors.
In this study no significant differences in tamoxifen-induced
relaxation were seen between arteries from male and female rabbits (Fig. 4a). Similarly, the involvement of NO and estrogen receptor in
the mechanism of this relaxation appeared identical in both sexes (Fig.
4, b and c). These results are similar to experiments with raloxifene
in the same model (Figtree et al., 1999
). However, conditions in this
rabbit model are significantly different to that in the human. In vitro
and in vivo concentrations do differ with regard to potency. This model
does not include effects of other circulating hormones, blood volume,
or coronary circulation. Arteries from female rabbits are continually
exposed to the high levels of estrogen of the estrous stage of the
cycle. This may result in a different acute response to sex steroids in
vitro compared with humans, in whom estrogen levels vary during the menstrual cycle, and are low after menopause.
We have shown that tamoxifen is able to act both via the endothelium
and directly on the vascular smooth muscle to induce relaxation of
epicardial coronary arterial rings from both male and female animals.
The former mechanism involves interaction with the estrogen receptor at
the level of the endothelium and stimulation of NO. With the increasing
use of tamoxifen as an adjuvant treatment for the treatment of breast
cancer patients, and the fall in mortality from breast cancer, the
effect of this treatment on the risk of cardiovascular disease, the
greatest cause of mortality in women in Western countries, becomes more important (Beral et al., 1995
). This highlights the importance of the
beneficial effects of tamoxifen on coronary artery vasomotion by a
mechanism that may contribute to an overall beneficial effect of
tamoxifen in protecting against cardiovascular disease (McDonald and
Stewart, 1991
; Early Breast Cancer Trialists' Collaborative Group,
1992
).
| |
Footnotes |
|---|
Accepted for publication July 7, 2000.
Received for publication December 23, 1999.
Send reprint requests to: Dr. Peter Collins, Cardiac Medicine, National Heart and Lung Institute, Imperial College School of Medicine, Dovehouse St., London, SW3 6LY, UK. E-mail: peter.collins{at}ic.ac.uk
| |
Abbreviations |
|---|
SERM, selective estrogen receptor modulator;
L-NAME, N
-nitro-L-arginine
methyl ester;
NO, nitric oxide.
| |
References |
|---|
|
|
|---|

Getting in on the action?
Nat Med
3:
493-494[Medline].
-Estradiol inhibits Ca2+ influx and Ca2+ release induced by thromboxane A2 in porcine coronary artery.
Circulation
91:
2619-2626
-estradiol on contraction, Ca2+ current and intracellular free Ca2+ in guinea pig isolated cardiac myocytes.
Br J Pharmacol
106:
739-745[Medline].
-estradiol in vitro.
Br J Pharmacol
104:
1033-1037[Medline].
-estradiol on rabbit coronary artery contractile responses to endothelin-1.
Am J Physiol
263:
H271-H275
-estradiol in vitro.
Cardiovasc Res
27:
1939-1942[Medline].This article has been cited by other articles:
![]() |
C. J. Mark, R. Tatchum-Talom, D. S. Martin, and K. M. Eyster Effects of estrogens and selective estrogen receptor modulators on vascular reactivity in the perfused mesenteric vascular bed Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2007; 293(5): R1969 - R1975. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Moritz, R. Gust, and H. H. Pertz Characterization of the Relaxant Response to N,N'-Dipropyl-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine in Porcine Coronary Arteries J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 699 - 706. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Pinna, C. Bolego, P. Sanvito, V. Pelosi, R. Baetta, A. Corsini, R. M. Gaion, and A. Cignarella Raloxifene Elicits Combined Rapid Vasorelaxation and Long-Term Anti-Inflammatory Actions in Rat Aorta J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1444 - 1451. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. P. Leung, X. Yao, C.-W. Lau, W.-H. Ko, L. Lu, and Y. Huang Raloxifene relaxes rat intrarenal arteries by inhibiting Ca2+ influx Am J Physiol Renal Physiol, July 1, 2005; 289(1): F137 - F144. [Abstract] [Full Text] [PDF] |
||||
![]() |
R I Nicholson, C Staka, F Boyns, I R Hutcheson, and J M W Gee Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy Endocr. Relat. Cancer, December 1, 2004; 11(4): 623 - 641. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-Y. Tsang, X. Yao, K. Essin, C.-M. Wong, F. L. Chan, M. Gollasch, and Y. Huang Raloxifene Relaxes Rat Cerebral Arteries In Vitro and Inhibits L-Type Voltage-Sensitive Ca2+ Channels Stroke, July 1, 2004; 35(7): 1709 - 1714. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-Y. Tsang, X. Yao, F. L. Chan, C.-M. Wong, Z.-Y. Chen, I. Laher, and Y. Huang Estrogen and Tamoxifen Modulate Cerebrovascular Tone in Ovariectomized Female Rats Hypertension, July 1, 2004; 44(1): 78 - 82. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Schiff, S. A. Massarweh, J. Shou, L. Bharwani, S. K. Mohsin, and C. K. Osborne Cross-Talk between Estrogen Receptor and Growth Factor Pathways as a Molecular Target for Overcoming Endocrine Resistance Clin. Cancer Res., January 1, 2004; 10(1): 331S - 336S. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Tschugguel, W. Dietrich, Z. Zhegu, F. Stonek, A. Kolbus, and J. C. Huber Differential Regulation of Proteasome-Dependent Estrogen Receptor {alpha} and {beta} Turnover in Cultured Human Uterine Artery Endothelial Cells J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 2281 - 2287. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Tatchum-Talom, C. Martel, F. Labrie, and A. Marette Acute vascular effects of the selective estrogen receptor modulator EM-652 (SCH 57068) in the rat mesenteric vascular bed Cardiovasc Res, February 1, 2003; 57(2): 535 - 543. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Stirone, S. P. Duckles, and D. N. Krause Multiple forms of estrogen receptor-alpha in cerebral blood vessels: regulation by estrogen Am J Physiol Endocrinol Metab, January 1, 2003; 284(1): E184 - E192. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||